Bing Yuan, PhD, MBA
Membership Committee Member & Founder, BioKatalyst
Chief Business Officer, CStone Pharmaceuticals
Dr. Bing Yuan is an oncology business executive experienced in business development, new product strategy, global product launch and brand life cycle management. At various stages, he made key contributions to 7 oncology drugs: Keytruda, Glivec, Afinitor, Jakavi, Zykadia, Halaven and Lenvima. Dr. Yuan is currently Executive Director and Global Lead, Oncology Business Development at Merck. He is in charge of worldwide search and evaluation of clinical stage Oncology assets. In particular, he focuses on expanding Merck's portfolio in cancer immunotherapy and strengthens Keytruda's market position in anti-PD1 /PD-L1 class. Before joining Merck, he held various global commercial positions with increasing responsibilities at Novartis Oncology, most recently as Executive Director and Head, Life Cycle Strategy for Glivec and Afinitor. His other roles included new product planning, early portfolio strategy, and BD evaluation. He participated in global launch of Zykadia in lung cancer and was a core deal team member that successfully in-licensed Jakavi. He was three-time Novartis Oncology President Award recipient. Before joining Novartis, he was global strategic marketing lead for Eisai’s entire Oncology portfolio. Dr. Yuan holds a BS in Biochemistry from Nanjing University, a Ph.D. in Molecular Biology from Columbia University and a MBA from Cornell University.